Advertisement
Organisation › Details
Apeiron (Group)
APEIRON Biologics AG is a European private biotechnology company based in Vienna, Austria, that specializes in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases. APEIRON’s APN01/alunacedase alfa (rhsACE2) is undergoing a Phase II trial to treat COVID-19. APEIRON Biologics has an approved product on the market, Qarziba®, for the treatment of pediatric neuroblastoma patients, which is outlicensed to and distributed worldwide by EUSA Pharma. The company’s clinical program APN401 is a first-in-class autologous cellular therapy to strengthen immune reactivity via targeting the intracellular master checkpoint, Cbl-b. APEIRON Biologics ´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions. *
Start | 2012-10-17 established | |
Industry | cancer immunotherapy (immuno-oncology, I-O) | |
Region | Wien (Vienna) | |
Country | Austria | |
Street | 5 Campus-Vienna-Biocenter | |
City | 1030 Wien | |
Tel | +43-1-865-6577 | |
Address record changed: 2020-12-11 | ||
Basic data | Employees | B: 11 to 50 (2015-09-22) |
* Document for »About Section«: Apeiron Biologics AG. (11/9/20). "Press Release: Apeiron Biologics AG and Domainex Ltd Announce the Expansion of Their Partnership to Progress Targeted Cancer Immune Therapy Drug Discovery". Vienna & Saffron Waldon. | ||
Record changed: 2023-07-10 |
Advertisement
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
» top